top of page
  • Trio Pharma and Ajinomoto Bio-Pharma Partner for Dual-Action Antibody Therapy Advancement
    SAN DIEGO and SAN FRANCISCO, April 30, 2020 /PRNewswire/ - Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, are pleased to announce a development collaboration agreement to evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.
  • Trio Pharmaceuticals Pioneers Next-Gen Cancer Therapy: Dual-Drug Antibody Conjugates to Revolutionize Treatment
    April 30, 2020 ADC Review | Journal of Antibody-drug Conjugates - Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies is that drugs that work by different mechanisms may be more effective since they may decrease or slow the likelihood of resistance.
  • TRIO Pharmaceuticals is Featured in San Diego Business Journal for Successful Closing of Oversubscribed Seed Round
    In March, the San Diego-based TRIO announced a $2.2 million seed round, led by local investors SeedFolio, NuFund Venture Group and Friedman BioVentures and also, from Purdue University’s endowment fund and Japan-based Newsight Tech Angels Inc.. The seed funding follows a $400,000 SBIR (Small Business Innovation Research) grant awarded to the company in September 2022.
  • The Endowment Fund of Purdue University Invests In TRIO Pharma's Seed Round
    WEST LAFAYETTE, Ind. – Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus. The company’s antibody-based therapeutics strengthens the body’s defense, the immune system, to eradicate cancer.
  • TRIO Is Featured as a Connect 2024 Cool Company
    If you’re searching for the latest innovative tech and life science companies in Southern California, check out Connect’s Class of 2024 Cool Companies. We’ve sifted through numerous submissions this year with the assistance of our esteemed judges to bring you the standout selections below.
bottom of page